Entera Bio Past Earnings Performance
Past criteria checks 0/6
Entera Bio has been growing earnings at an average annual rate of 2.8%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been declining at an average rate of 33.4% per year.
Key information
2.8%
Earnings growth rate
23.2%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -33.4% |
| Return on equity | -142.3% |
| Net Margin | -9,270.7% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate
Jul 12
Here's Why We're Not Too Worried About Entera Bio's (NASDAQ:ENTX) Cash Burn Situation
Mar 23We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate
May 31Will Entera Bio (NASDAQ:ENTX) Spend Its Cash Wisely?
Feb 15Is Entera Bio (NASDAQ:ENTX) In A Good Position To Deliver On Growth Plans?
Oct 13Entera Bio GAAP EPS of -$0.24 , revenue of $0.11M
Aug 11We Think Entera Bio (NASDAQ:ENTX) Needs To Drive Business Growth Carefully
Jun 10Companies Like Entera Bio (NASDAQ:ENTX) Are In A Position To Invest In Growth
Jan 21We're Interested To See How Entera Bio (NASDAQ:ENTX) Uses Its Cash Hoard To Grow
Oct 06Here's Why We're Not Too Worried About Entera Bio's (NASDAQ:ENTX) Cash Burn Situation
Jun 19Entera Bio secures European patent for oral PTH formulations
Jun 17We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate
Mar 20Here's Why Entera Bio (NASDAQ:ENTX) Must Use Its Cash Wisely
Dec 05
Revenue & Expenses Breakdown
How Entera Bio makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -9 | 5 | 4 |
| 30 Jun 24 | 0 | -9 | 4 | 4 |
| 31 Mar 24 | 0 | -9 | 4 | 4 |
| 31 Dec 23 | 0 | -9 | 4 | 5 |
| 30 Sep 23 | 0 | -10 | 6 | 5 |
| 30 Jun 23 | 0 | -11 | 6 | 5 |
| 31 Mar 23 | 0 | -11 | 7 | 5 |
| 31 Dec 22 | 0 | -13 | 8 | 6 |
| 30 Sep 22 | 0 | -14 | 7 | 7 |
| 30 Jun 22 | 0 | -14 | 7 | 8 |
| 31 Mar 22 | 0 | -14 | 7 | 7 |
| 31 Dec 21 | 1 | -12 | 6 | 7 |
| 30 Sep 21 | 1 | -12 | 5 | 5 |
| 30 Jun 21 | 1 | -10 | 5 | 5 |
| 31 Mar 21 | 0 | -11 | 5 | 6 |
| 31 Dec 20 | 0 | -11 | 5 | 6 |
| 30 Sep 20 | 0 | -11 | 5 | 7 |
| 30 Jun 20 | 0 | -13 | 5 | 7 |
| 31 Mar 20 | 0 | -11 | 5 | 7 |
| 31 Dec 19 | 0 | -11 | 4 | 7 |
| 30 Sep 19 | 1 | -10 | 4 | 7 |
| 30 Jun 19 | 1 | -12 | 4 | 7 |
| 31 Mar 19 | 1 | -9 | 3 | 8 |
| 31 Dec 18 | 1 | -10 | 3 | 9 |
| 30 Sep 18 | 0 | -11 | 5 | 8 |
| 30 Jun 18 | 0 | -10 | 7 | 6 |
| 31 Mar 18 | 0 | -13 | 8 | 5 |
| 31 Dec 17 | 0 | -11 | 9 | 3 |
| 30 Sep 17 | 0 | -8 | 6 | 2 |
| 30 Jun 17 | 0 | -6 | 4 | 3 |
| 31 Mar 17 | 0 | -4 | 3 | 3 |
| 31 Dec 16 | 0 | -1 | 3 | 3 |
Quality Earnings: ENTX is currently unprofitable.
Growing Profit Margin: ENTX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ENTX is unprofitable, but has reduced losses over the past 5 years at a rate of 2.8% per year.
Accelerating Growth: Unable to compare ENTX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ENTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: ENTX has a negative Return on Equity (-142.25%), as it is currently unprofitable.